Gilead Sciences

GILD
Delayed Nasdaq - 02/19 10:00:01 pm
66.76USD
-1.23%
Prev.67.5900
Open67.3400
High67.7700
Low66.6500
Volume6 396 202
Financials
Sales 2019 21 974 M
EBIT 2019 11 241 M
R. net 2019 6 595 M
Debt 2019 6 341 M
Rend. 2019 3,79%
P/E ratio 2019 13,00
P/E ratio 2020 11,73
EV / Sales 2019 4,22x
EV / Sales 2020 3,65x
Capitalization 86 362 M
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.3%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (90.9% of net sales) and other (9.1%; primarily...
Sector :
Bio Therapeutic Drugs
Calendar :
2019-03-14 GILEAD SCIENCES : Ex-dividend day for
Trading Rating :
Investor Rating :
Latest news
02/19GILEAD SCIENCES : Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
AQ
02/14GILEAD SCIENCES : Stock Slides Lower on NASH Drug Failure
AQ
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Government Shutdown, Trade Optimism
DJ
02/12Coty and Electronic Arts surge while Molson Coors dips
AQ
02/12GILEAD SCIENCES : Announces Topline Data from Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
AQ
02/11GILEAD SCIENCES : Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
BU
02/05GILEAD SCIENCES : Ralph Lauren surges, Gilead sinks
AQ
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Update
DJ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance67,979,077,9
Spread/Res.-1,6%-15%-14%
Spread/Supp.2,1%10%7,9%
Support65,460,561,9